All questions are shown as received by the Trust.
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
e. Aromatase Inhibitor as a single agent
f. Atezolizumab
g. Capecitabine as a single agent
h. Carboplatin + Paclitaxel
i. Eribulin as a single agent or in combination
j. Everolimus + Exemestane
k. Fulvestrant as a single agent
l. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
m. Palbociclib + Fulvestrant
n. Parp Inhibitors (Olaparib/Talazoparib)
o. Pembrolizumab
p. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
q. Ribociclib + Fulvestrant
r. Sacituzumab Govitecan
s. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
t. Transtuzumab deruxtecan
u. Trastuzumab as a single agent or in combination
v. Trastuzumab emtansine
w. Any other active systemic anti-cancer therapy
Q2. If breast cancer is not treated at or within the Trust, where are patients referred?
